Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer.
angiogenesis
biomarkers
immunotherapy
prognosis
renal cell carcinoma
targeted therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
04
08
2019
accepted:
27
11
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
11
1
2020
Statut:
epublish
Résumé
In the last decades, the prognosis of metastatic renal cell carcinoma (mRCC) has remarkably improved following the advent of the "targeted therapy" era. The expanding knowledge on the prominent role played by angiogenesis in RCC pathogenesis has led to approval of multiple anti-angiogenic agents such as sunitinib, pazopanib, axitinib, cabozantinib, sorafenib, and bevacizumab. These agents can induce radiological responses and delay cancer progression for months or years before onset of resistance, with a clinically meaningful activity. The need for markers of prognosis and efficacy of anti-angiogenic agents has become more compelling as novel systemic immunotherapy agents have also been approved in RCC and can be administered as an alternative to angiogenesis inhibitors. Anti PD-1 monoclonal antibody nivolumab has been approved in the second-line setting after tyrosine kinase inhibitors failure, while combination of nivolumab plus anti CTLA-4 monoclonal antibody ipilimumab has been approved as first-line therapy of RCC patients at intermediate or poor prognosis. In this review article, biomarkers of prognosis and efficacy of antiangiogenic therapies are summarized with a focus on those that have the potential to affect treatment decision-making in RCC. Biomarkers predictive of toxicity of anti-angiogenic agents have also been discussed.
Identifiants
pubmed: 31921657
doi: 10.3389/fonc.2019.01400
pmc: PMC6917607
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1400Informations de copyright
Copyright © 2019 D'Aniello, Berretta, Cavaliere, Rossetti, Facchini, Iovane, Mollo, Capasso, Pepa, Pesce, D'Errico, Buonerba, Di Lorenzo, Pisconti, De Vita and Facchini.
Références
Cancer. 2011 Feb 1;117(3):534-44
pubmed: 20845482
Curr Cancer Drug Targets. 2018;18(5):468-479
pubmed: 28183256
Clin Genitourin Cancer. 2019 Jun;17(3):e689-e703
pubmed: 31072748
J Mol Diagn. 2015 Mar;17(2):136-44
pubmed: 25555365
Clin Genitourin Cancer. 2019 Oct;17(5):e981-e994
pubmed: 31229459
J Urol. 1997 Apr;157(4):1482-6
pubmed: 9120987
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Cell Rep. 2016 Mar 15;14(10):2476-89
pubmed: 26947078
Eur Urol. 2014 Jul;66(1):77-84
pubmed: 24613583
Front Pharmacol. 2016 Dec 05;7:468
pubmed: 27924140
Eur Urol. 2019 Dec;76(6):861-867
pubmed: 31445844
J Clin Endocrinol Metab. 2007 Sep;92(9):3531-4
pubmed: 17595247
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
Cancer Cell. 2016 Jan 11;29(1):104-116
pubmed: 26766592
Clin Cancer Res. 2015 Jan 15;21(2):365-72
pubmed: 25411163
Clin Cancer Res. 2007 Mar 15;13(6):1757-61
pubmed: 17363529
N Engl J Med. 2005 Dec 8;353(23):2477-90
pubmed: 16339096
Cancer Biol Ther. 2014 Mar 1;15(3):329-41
pubmed: 24351440
Clin Cancer Res. 2008 Aug 1;14(15):4726-34
pubmed: 18676741
Eur Urol. 2012 Feb;61(2):258-68
pubmed: 22030119
Clin Genitourin Cancer. 2018 Jun;16(3):e605-e612
pubmed: 29239846
Oncologist. 2010;15(11):1135-46
pubmed: 21051659
J Urol. 1995 Jul;154(1):28-31
pubmed: 7776446
J Clin Oncol. 2008 Aug 1;26(22):3743-8
pubmed: 18669461
Front Pharmacol. 2016 Sep 28;7:331
pubmed: 27733829
Nat Med. 2009 Sep;15(9):1023-30
pubmed: 19668192
J Clin Oncol. 2010 May 1;28(13):2144-50
pubmed: 20368553
Lancet Oncol. 2009 Aug;10(8):757-63
pubmed: 19615940
Am Soc Clin Oncol Educ Book. 2015;:e239-47
pubmed: 25993179
Clin Cancer Res. 2011 Aug 15;17(16):5443-50
pubmed: 21828239
Clin Cancer Res. 2009 Dec 15;15(24):7582-7592
pubmed: 19996202
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
Eur J Cancer. 2013 Apr;49(6):1287-96
pubmed: 23321547
Acta Oncol. 2018 Apr;57(4):498-508
pubmed: 29095068
Invest New Drugs. 2012 Dec;30(6):2443-9
pubmed: 22644070
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
Front Pharmacol. 2016 Aug 31;7:287
pubmed: 27630568
FASEB J. 2004 Feb;18(2):338-40
pubmed: 14657001
Eur J Cancer. 2019 Feb;108:33-40
pubmed: 30616146
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Clin Cancer Res. 2010 Oct 1;16(19):4853-63
pubmed: 20651059
Br J Cancer. 2015 Mar 31;112(7):1190-8
pubmed: 25695485
Eur Urol Oncol. 2019 Nov;2(6):708-715
pubmed: 31588018
Hum Mol Genet. 2012 Jan 15;21(2):456-62
pubmed: 22010048
Cancer Immunol Immunother. 1992;35(2):97-105
pubmed: 1596939
Genes Cancer. 2010 Feb 1;1(2):152-163
pubmed: 20871783
J Urol. 2008 Sep;180(3):860-5; discussion 865-6
pubmed: 18635227
PLoS One. 2011;6(7):e21260
pubmed: 21818257
Eur Urol. 2017 Dec;72(6):962-971
pubmed: 28262413
Eur J Cancer. 2013 Jun;49(9):2134-42
pubmed: 23518211
J Clin Oncol. 2000 May;18(9):1928-35
pubmed: 10784634
Jpn J Clin Oncol. 2010 Dec;40(12):1166-72
pubmed: 20713418
Eur J Cancer. 2012 Feb;48(3):333-9
pubmed: 22209391
Oncotarget. 2017 Jan 3;8(1):1204-1212
pubmed: 27901483
ESMO Open. 2016 May 25;1(3):e000013
pubmed: 27843601
Curr Cancer Drug Targets. 2012 Jul;12(6):693-702
pubmed: 22463589
World J Urol. 2018 Dec;36(12):1899-1911
pubmed: 30099580
Biochem Biophys Res Commun. 2008 Oct 24;375(3):287-91
pubmed: 18680722
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Lancet Oncol. 2011 Nov;12(12):1143-50
pubmed: 22015057
PLoS One. 2014 Jan 24;9(1):e86263
pubmed: 24475095
Cancer Discov. 2019 Apr;9(4):510-525
pubmed: 30622105
Drugs. 2013 Apr;73(5):427-38
pubmed: 23572408
BMC Med. 2012 Sep 27;10:112
pubmed: 23016578
Nat Genet. 2011 Jan;43(1):60-5
pubmed: 21131975
Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H107-18
pubmed: 16126815
Lancet Oncol. 2012 Aug;13(8):827-37
pubmed: 22759480
Eur J Cancer. 2019 Jun;114:67-75
pubmed: 31075726
J Clin Oncol. 2006 Mar 20;24(9):1363-9
pubmed: 16446323
Eur Urol. 2010 Dec;58(6):906-11
pubmed: 20884115
Clin Genitourin Cancer. 2015 Aug;13(4):280-286
pubmed: 25442773
Int J Mol Sci. 2019 Apr 26;20(9):
pubmed: 31027366
Genes Chromosomes Cancer. 2014 Jan;53(1):38-51
pubmed: 24166983
J Urol. 2013 May;189(5):1930-8
pubmed: 23206420
Thyroid. 2007 Apr;17(4):351-5
pubmed: 17465866
Clin Cancer Res. 2013 Sep 15;19(18):5218-26
pubmed: 23881929
BJU Int. 2007 May;99(5 Pt B):1282-8
pubmed: 17441925
Br J Dermatol. 2008 Mar;158(3):592-6
pubmed: 18070211
EPMA J. 2015 Oct 20;6:20
pubmed: 26500709
Clin Genitourin Cancer. 2017 Aug;15(4):e609-e614
pubmed: 28108284
Lancet Oncol. 2013 Feb;14(2):159-167
pubmed: 23333114
Eur Urol. 2017 Jun;71(6):979-985
pubmed: 27899233
Cancer. 2012 Apr 1;118(7):1946-54
pubmed: 21882181
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
J Clin Oncol. 2015 May 1;33(13):1430-7
pubmed: 25452452
Clin Cancer Res. 2013 Jul 1;19(13):3681-92
pubmed: 23685835
Ann Oncol. 2016 Jul;27(7):1304-11
pubmed: 27059553
J Clin Oncol. 2004 Feb 1;22(3):454-63
pubmed: 14752067
Clin Cancer Res. 2015 Mar 15;21(6):1329-39
pubmed: 25583177
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Ann Oncol. 2014 Nov;25(11):2178-2184
pubmed: 25193987
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
BJU Int. 2010 Sep;106(6):772-8
pubmed: 20230385
J Exp Clin Cancer Res. 2009 Mar 20;28:40
pubmed: 19302703
Eur J Cancer. 2012 May;48(7):1023-30
pubmed: 22436979
Front Oncol. 2019 Jun 21;9:479
pubmed: 31293962
J Clin Oncol. 2008 Nov 20;26(33):5422-8
pubmed: 18936475
Clin Endocrinol (Oxf). 2008 Oct;69(4):669-72
pubmed: 18394019
Arch Pathol Lab Med. 2012 May;136(5):490-5
pubmed: 22229848
J Transl Med. 2007 Jul 02;5:32
pubmed: 17605814
Br J Cancer. 2017 Aug 8;117(4):478-484
pubmed: 28683470
J Natl Cancer Inst. 2007 Jan 3;99(1):81-3
pubmed: 17202116
Eur Urol. 2018 Oct;74(4):474-480
pubmed: 29463434
Pharmacogenet Genomics. 2017 Jun;27(6):227-231
pubmed: 28430711
Anticancer Drugs. 2009 Nov;20(10):893-900
pubmed: 19752718
BMC Med. 2010 Oct 21;8:64
pubmed: 20964835
Am J Pathol. 2015 Mar;185(3):693-703
pubmed: 25572155
Expert Opin Biol Ther. 2016 Nov;16(11):1387-1401
pubmed: 27463642
Pediatr Nephrol. 2015 May;30(5):727-40
pubmed: 24928414
Clin Genitourin Cancer. 2015 Aug;13(4):328-337.e3
pubmed: 25816720
N Engl J Med. 2007 Apr 12;356(15):1580; author reply 1580-1
pubmed: 17429091
Exp Mol Med. 2008 Feb 29;40(1):71-83
pubmed: 18305400
Lancet Oncol. 2016 Jul;17(7):917-927
pubmed: 27279544
Ann Oncol. 2008 Nov;19(11):1955-61
pubmed: 18550575
Tumori. 2014 Nov-Dec;100(6):e305-8
pubmed: 25688517
Ann Oncol. 2015 Feb;26(2):378-85
pubmed: 25467013
Cancer Res. 2010 Feb 1;70(3):1063-71
pubmed: 20103651
Biochim Biophys Acta. 2015 May;1854(5):410-25
pubmed: 25617660
Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50
pubmed: 25100134
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Clin Cancer Res. 2011 Feb 1;17(3):620-9
pubmed: 21097692
Target Oncol. 2013 Sep;8(3):203-209
pubmed: 23300029
J Clin Oncol. 2002 Jan 1;20(1):289-96
pubmed: 11773181
Curr Signal Transduct Ther. 2014 Dec;8(3):210-218
pubmed: 25152703
Oncologist. 2017 Mar;22(3):286-292
pubmed: 28220024
Cancer. 2011 Mar 15;117(6):1183-9
pubmed: 20960527
BJU Int. 2012 Dec;110(11):1747-53
pubmed: 23106948
Front Oncol. 2018 Nov 02;8:456
pubmed: 30450335
J Clin Oncol. 2009 Jul 10;27(20):3312-8
pubmed: 19451442
Ann Oncol. 2002 Sep;13(9):1460-8
pubmed: 12196373
Ann Oncol. 2009 Feb;20(2):393-4
pubmed: 19211503
Br J Cancer. 2013 Mar 19;108(5):1133-42
pubmed: 23449350
Eur Urol. 2011 Oct;60(4):644-61
pubmed: 21741163
Nat Genet. 2012 Jun 10;44(7):751-9
pubmed: 22683710
Br J Cancer. 2014 Jun 10;110(12):2821-8
pubmed: 24823696
Nature. 2010 Jan 21;463(7279):360-3
pubmed: 20054297
J BUON. 2014 Jan-Mar;19(1):15-21
pubmed: 24659637
J Clin Oncol. 2011 Jun 20;29(18):2557-64
pubmed: 21576632
Nat Genet. 2014 Mar;46(3):225-233
pubmed: 24487277
J Clin Oncol. 2009 Aug 1;27(22):3584-90
pubmed: 19487381
Nature. 2011 Jan 27;469(7331):539-42
pubmed: 21248752
Ann Oncol. 2012 Mar;23(3):714-721
pubmed: 21653681
J Urol. 2002 Dec;168(6):2395-400
pubmed: 12441925
Biochim Biophys Acta. 2014 Dec;1846(2):638-54
pubmed: 25450580